Jessica Walters

FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.

New research maps an mPFC–zona incerta circuit that drives punishment-resistant binge eating and hints at personalized brain stimulation targets for better treatment.

Catch up on last week's news in psychiatry.

Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.

Catch up on psychiatry news from last week.

Review the developments in GLP-1s in 2026.

ACP outlines ethical AI use in medicine—protect patient trust, curb bias, prevent deskilling, and guide transparent, equitable care.

Review news in psychiatry from the last week.

New donanemab dosing cuts ARIA-E risk, speeds MRI monitoring, and shows durable 3-year benefits with lasting biomarker gains in early Alzheimer’s.

Recap Alzheimer disease updates from August.

Plasma P-tau217 blood tests match amyloid PET for early Alzheimer pathology, offering scalable, noninvasive detection and forecasting cognitive decline risk years ahead.

See the latest in this psychiatric news roundup.

A quick recap of the last week in psychiatric news.

FDA approves PET imaging agent for Alzheimer disease tau pathology.

KINECT-PRO shows Ingrezza eases tardive dyskinesia movements and boosts daily function and quality of life, even across psychiatric diagnoses.

New data show once-daily CTx-1301 delivers 3 timed dexmethylphenidate releases for faster onset, steadier late-day ADHD coverage, tolerability.

Review the latest developments in narcolepsy treatment.

Review the latest in psychiatry from the last week.

FDA approves Takeda’s Orzeyful, first orexin agonist, improving wakefulness and reducing cataplexy in adults with narcolepsy type 1 in pivotal trials.

New Alzheimer trial news highlights safer anti-amyloid PMN310, cannabinoids easing agitation, tau gene therapy progress, FDA Fast Track psychosis drug, and TBI inflammation targets.

FDA clears first triple reuptake ADHD drug Simtriyo, offering nonstimulant relief for adults and kids 6+ with executive and emotional symptoms.

From long-acting antipsychotics to psilocybin and new ADHD meds, clinicians weigh emerging therapies reshaping depression and postpartum care.

How can new Alzheimer therapies benefit patients today?

New data show post‑TBI inflammation boosts amyloid; blocking soluble TNF with XPro1595 preserves memory and reduces pain, hinting prevention.

PMN310 shows strong 6‑month safety in early Alzheimer disease, with zero ARIA‑E and encouraging tau biomarker shifts before 2027 data.

After TBI, soluble TNF sparks Alzheimer-like damage; XPro1595 blocks it in mice, preserving memory and reducing pain—hinting prevention.

FDA clears Simtriyo, a first-in-class NDSRI and central nervous system stimulant for ADHD, offering new symptom and executive-function gains.

Review centanafadine ahead of the upcoming FDA decision on July 24.

ASCP updates spotlight ketamine safety guardrails, at‑home agitation therapy, psilocybin phase 3 momentum, and biomarker-driven precision psychiatry.

Top 2026 psychiatry conference takeaways: mixed-feature bipolar care, GLP-1 addiction trials, schizophrenia adherence, TD gaps, AI prodrome screening.